Orexigen Therapeutics, Inc.
) entered into a commercial supply agreement with
) for its obesity drug, Contrave, for territories outside North
America. As per the terms of the agreement, Sanofi will
manufacture Contrave at one of the facilities in France.
ACTELION LTD (ALIOF): Get Free Report
OREXIGEN THERAP (OREX): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
TAKEDA PHARMACT (TKPYY): Get Free Report
To read this article on Zacks.com click here.
In Oct 2013, Orexigen submitted a marketing authorization
application to the European Medicines Agency for Contrave with a
final decision expected in the second half of 2014. Subject to
regulatory approval, the company plans to launch the drug in
early 2015. The company is working on ensuring that Contrave is
ready for global supply, once approved.
We note that a randomized, double-blind, placebo-controlled Light
Study (n = 8,900) is being conducted to assess the risk of major
adverse cardiovascular events in overweight and obese subjects
treated with Contrave. The company expects data from the Light
study to be available for the Committee for Medicinal Products
for Human Use Day 120 List of Questions.
Orexigen expects to carry out an interim analysis from the Light
Study by early December. The study is being conducted under a
Special Protocol Assessment with the U.S. Food and Drug
Administration (FDA). Based on the outcome of interim analysis,
the company plans to re-submit the new drug application for
Contrave to the FDA by the end of this year.
We remind investors that the company had received a complete
response letter (CRL) from the FDA in Jan 2011 for Contrave. At
the time of issuing the CRL, the FDA had expressed concerns
regarding the long-term cardiovascular safety profile of
Contrave, and had asked Orexigen to conduct an additional study.
The company has a collaboration agreement with
Takeda Pharmaceutical Company Ltd
) for the development and commercialization of Contrave in North
However, we note that Contrave, once launched, will be a late
entrant in the obesity market. Last year, two obesity drugs,
Belviq and Qsymia, were approved.
Orexigen carries a Zacks Rank #4 (Sell). At present, companies
) look well-positioned with a Zacks #1 Rank (Strong Buy).